UTRECHT, Netherlands, and CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Merus NV (Nasdaq: MRUS) (“Merus,” “the Company,” “we” or “our”), a clinical-stage oncology that is developing innovative, full-length, multispecific antibodies (Biclonics® and Triclonics®), today announced the selection of an abstract for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois, June 3-7. 2022.
The presentation will highlight updated interim clinical data for the targeted bispecific antibody, zenocutuzumab (Zeno), in NRG1 gene fusion positive (NRG1+) cancer. Merus is currently recruiting patients for the Phase 1/2 eNRGy trial to assess the safety and antitumor activity of Zeno monotherapy in NRG1+ cancer.
Title : Efficacy and Safety of Zenocutuzumab, a HER2 x HER3 Bispecific Antibody, in Advanced NRG1 (NRG1+) Fusion Cancers
Main author:Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York
Abstract number: 105
Session title:Clinical Science Symposium, Bispecifics: Are Two Better Than One?
Session date and time: June 5, 2022, from 9:45 a.m. to 11:15 a.m. (CT).
The summary highlighting the interim clinical data will be available May 26 at 5:00 p.m. (ET) and an oral presentation, containing an analysis of the updated interim clinical data, will be delivered to meeting attendees and via live stream to attendees of the online meeting only, during the session titled “Clinical Science Symposium, Bispecifics: Are Two Better Than One?” on June 5 from 9:45 a.m. to 11:15 a.m. (CT). The presentation will also be available on the Merus website shortly after the live presentation.
We continue to be encouraged by the ongoing trial, have observed the clinical activity and safety profile and look forward to sharing an update of the interim clinical data in the summary from May 26 and at ASCO on June 5.
Company conference call and webcast information
Merus will host an investor conference call and webcast on Sunday, June 5, 2022 at 6:00 p.m. (CT) to discuss updated interim clinical data. A replay will be available after the call ends in the Investors and Media section of our website.
Zeno is a Biclonics® antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) which uses the Merus Dock & Block® mechanism to inhibit the neuregulin/HER3 tumor signaling pathway in solid tumors with NRG1 gene fusions (NRG1+). Through its unique mechanism of binding to HER2 receptors and potently blocking the interaction of NRG1 fusion proteins with HER3 receptors, Zeno has the potential to be particularly effective against NRG1+ cancers. In preclinical studies, Zeno also potently inhibits the formation of HER2/HER3 heterodimers and tumor growth in models harboring NRG1 gene fusions.
Learn more about Zeno Dock & Block®please visit https://merus.nl/technology/.
About Merus NV
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapies called Multiclonics®. The Multiclonics® are manufactured using industry standard processes. Preclinical and clinical studies have shown that they possess many of the same characteristics as conventional human monoclonal antibodies, including a long half-life and low immunogenicity. For further information, please consult the Merus website: http://www.merus.nl as well as https://twitter.com/MerusNV.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to historical facts should be considered forward-looking statements, including, but not limited to, statements regarding the clinical development of zenocutuzumab, future clinical trial results or interim data, clinical activity and safety profile of Zeno in the ongoing eNRGy trial as well as the planned presentation and investor conference. These forward-looking statements are based on management’s current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to differ materially from any results, performance or future achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional financing, which may not be available and which may require us to restrict our operations or require us to waive the rights to our Biclonics technologies®Triclonics® and multispecific antibody candidates; potential delays in regulatory approval, which could affect our ability to commercialize our product candidates and affect our ability to generate revenues; the lengthy and costly process of developing clinical drugs, the outcome of which is uncertain; the unpredictability of our early-stage development efforts for marketable drugs; potential delays in patient enrollment, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the possibility that such third parties may not perform satisfactorily; the effects of the COVID-19 pandemic; we may not identify Biclonics candidates® or appropriate bispecific antibodies in our collaborations or our collaborators may not work well in our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impede our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors, and our patent applications may be found not to comply with rules and regulations governing patents; we may not prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or held to be generic or determined to infringe other trademarks.
These and other important factors discussed under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and filed with the Securities and Exchange Commission, or SEC, on December 28, 2021. February 2022, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. Although we may elect to update such forward-looking statements at any time, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Biclonics®Triclonics® and Multiclonics® are registered trademarks of Merus NV